- Erbi Biosystems recently announced it raised $4 million in funding. These are the details.
Erbi Biosystems – the developer of innovative, small-scale, automated, and high-performance cell culture systems – recently announced it raised $4 million in funding. This latest funding round will enable the company to expand operations to meet the growing demand for its Breez perfusion bioreactor product and develop extensions to enhance cell therapy applications.
The Erbi Breez bioreactor is konwn for providing continuous media addition, cell retention and bubble-free gas diffusion through its True Perfusion technology, which is unique among existing small-scale bioreactors that can only approximate perfusion with intermittent media exchange. And the Breez’s fully automated, sterile, single-use system also includes online sensing and controls that are combined with easy-to-use software, delivering sophisticated feeding strategies, cell concentration, and media exchanges, resulting in performance that can exceed stirred tank and rocking bag reactors.
Last year, Erbi Biosystems doubled its staff and relocated to a larger facility north of Cambridge, equipped with biolabs and cleanroom manufacturing space.
KEY QUOTES:
“Erbi has developed a compelling platform for small-scale cell culture. In addition to its capabilities in bioprocessing, their platform enables testing of multiple replicates from a single sample of scarce patient cells – a unique and powerful capability that will accelerate cell therapy development.”
— Michael Chambers, Erbi investor and founding CEO of Aldevron
“The Breez product has proven to be an effective scale-down tool for process development across a range of cell types. The small volume, single-use, sterile and fully-automated format makes this an ideal platform for cell therapy manufacturing.”
— Dr. Martin Madaus, former Chairman and CEO of Millipore
“We’re growing quickly and expect to double again in 2022. Revenue from our growing list of Breez customers in the US, Europe and Asia is fueling our growth. This additional funding allows us to accelerate our pipeline of technology and product development projects which are focused on the needs of the cell therapy process development and GMP manufacturing.”
— Dr. Michael Chiu, CEO of Erbi Biosystems
Chambers and Dr. Madaus are both investors in the latest private round.
